Previous 10 | Next 10 |
Alaunos Therapeutics press release (NASDAQ:TCRT): Q1 GAAP EPS of -$0.05 beats by $0.02. As of March 31, 2022, Alaunos had approximately $68.3 million in cash and cash equivalents. The Company anticipates its cash runway will be sufficient to fund operations into the second quarter of 20...
Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications Will present preclinical data today at the ASGCT 25 th Annual Meeting highlighting the potential of mbIL-15 as a potent and ...
Alaunos Therapeutics (NASDAQ:TCRT) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.07 Over the last 1 year, TCRT has beaten EPS estimates 0% of the time and has beaten revenue estimates 0% of the time. Over the last 3 mon...
BITF, CGEN, CLSN, CMRX, OTCQB:CVSI, GOED, KALA, LTRY, LUNA, MNMD, NOVN, OEG, PLX, PTE, SOHU, SSYS, SYN, SYRS, TCRT, WEJO, WIX, WRBY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
In a little over a year, the market has gone from sell "old economy", companies that make something and earn money, to sell companies that don’t make things and earn money. We are now at the stage where nobody cares. don’t buy anything, whether it makes makes "things" or...
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice...
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. mar...
Wells Fargo has upgraded Alaunos Therapeutics (NASDAQ:TCRT) to overweight from equal weight citing the company's recent first patient dosing of TCR-T cell therapy in a phase 1/2 trial across multiple solid tumor indications. The firm has a $3 price target (~436% upside based on Tuesday's...
Every retail trader wants to find penny stocks with huge potential. Thanks to the rise of the “Ape” movement, the opportunity in the market was presented during the early days of the pandemic. Weathered stocks like GameStop ( NYSE: GME ) or Bed Bath & Beyond ( NASDAQ...
Preclinical data to be presented highlights the potential ability to generate mbIL-15 TCR-T cells targeting hotspot mutations expressed in solid tumors with enhanced survival capacity HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” o...
News, Short Squeeze, Breakout and More Instantly...
Alaunos Therapeutics Inc. Company Name:
TCRT Stock Symbol:
NASDAQ Market:
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...